Susan Halabi

Overview:

Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Positions:

Professor of Biostatistics & Bioinformatics

Biostatistics & Bioinformatics
School of Medicine

Chief, Division of Biostatistics

Biostatistics & Bioinformatics
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 1994

University of Texas Health Sciences Center, Houston

Grants:

PCRP Clinical Consortium: Duke University Clinical Research Site

Administered By
Medicine, Medical Oncology
Awarded By
Department of Defense
Role
Co Investigator
Start Date
End Date

Developing and Validating Prognostic Models of Clinical Outcomes In Men With Castration Resistant Prostate Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
National Institutes of Health
Role
Principal Investigator
Start Date
End Date

Surrogate Endpoints of Overall Survival in Men with Metastatic Hormone Sensitive Prostate Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
Prostate Cancer Foundation
Role
Principal Investigator
Start Date
End Date

Precision Medicine in Platinum-treated Lethal Bladder Cancer

Administered By
Biostatistics & Bioinformatics
Awarded By
Memorial Sloan Kettering Cancer Center
Role
Principal Investigator
Start Date
End Date

Serum Androgens and Survival in CRPC

Administered By
Duke Cancer Institute
Awarded By
University of California - San Francisco
Role
Principal Investigator
Start Date
End Date

Publications:

978P Pertuzumab plus trastuzumab (P+T) in patients (pts) with lung cancer (LC) with ERBB2 mutation (mut) or amplification (amp): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study

Authors
Ganti, AK; Rothe, M; Mangat, PK; Garrett-Mayer, E; Dib, EG; Duvivier, H; Ahn, E; Behl, D; Borghaei, H; Balmanoukian, AS; Gaba, A; Li, R; Osei-Boateng, K; Thota, R; O'Lone, R; Grantham, GN; Halabi, S; Schilsky, RL
MLA Citation
URI
https://scholars.duke.edu/individual/pub1559999
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S997
End Page
S998
DOI
10.1016/j.annonc.2022.07.1106

501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19

Authors
Halabi, S; Luo, B; Dzimitrowicz, H; Hwang, C; Wise-Draper, TM; Labaki, C; McKay, RR; Ruiz, E; Rangel-Escareño, C; Farmakiotis, D; Griffiths, EA; Jani, CT; Accordino, M; Friese, C; Wulff-Burchfield, E; Puc, M; Yu, P; Topaloglu, U; Mishra, S; Warner, J
MLA Citation
Halabi, S., et al. “501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S771–72. Crossref, doi:10.1016/j.annonc.2022.07.629.
URI
https://scholars.duke.edu/individual/pub1560000
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S771
End Page
S772
DOI
10.1016/j.annonc.2022.07.629

98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study

Authors
Ahn, E; Rothe, M; Mangat, PK; Garrett-Mayer, E; Al Baghdadi, T; Baron, AD; Krauss, JC; Balmanoukian, AS; Bauman, JR; Hameed, MK; Mileham, KF; Thota, R; Gold, PJ; Meric-Bernstam, F; Powell, SF; Yang, ES; O'Lone, R; Grantham, GN; Halabi, S; Schilsky, RL
MLA Citation
Ahn, E., et al. “98P Olaparib (O) in patients (pts) with solid tumors with BRCA1/2 mutation (mut): Results from the targeted agent and profiling utilization registry (TAPUR) study.” Annals of Oncology, vol. 33, Elsevier BV, 2022, pp. S583–84. Crossref, doi:10.1016/j.annonc.2022.07.130.
URI
https://scholars.duke.edu/individual/pub1560002
Source
crossref
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S583
End Page
S584
DOI
10.1016/j.annonc.2022.07.130

Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022.

BACKGROUND: Innovations in imaging and molecular characterisation and the evolution of new therapies have improved outcomes in advanced prostate cancer. Nonetheless, we continue to lack high-level evidence on a variety of clinical topics that greatly impact daily practice. To supplement evidence-based guidelines, the 2022 Advanced Prostate Cancer Consensus Conference (APCCC 2022) surveyed experts about key dilemmas in clinical management. OBJECTIVE: To present consensus voting results for select questions from APCCC 2022. DESIGN, SETTING, AND PARTICIPANTS: Before the conference, a panel of 117 international prostate cancer experts used a modified Delphi process to develop 198 multiple-choice consensus questions on (1) intermediate- and high-risk and locally advanced prostate cancer, (2) biochemical recurrence after local treatment, (3) side effects from hormonal therapies, (4) metastatic hormone-sensitive prostate cancer, (5) nonmetastatic castration-resistant prostate cancer, (6) metastatic castration-resistant prostate cancer, and (7) oligometastatic and oligoprogressive prostate cancer. Before the conference, these questions were administered via a web-based survey to the 105 physician panel members ("panellists") who directly engage in prostate cancer treatment decision-making. Herein, we present results for the 82 questions on topics 1-3. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Consensus was defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. RESULTS AND LIMITATIONS: The voting results reveal varying degrees of consensus, as is discussed in this article and shown in the detailed results in the Supplementary material. The findings reflect the opinions of an international panel of experts and did not incorporate a formal literature review and meta-analysis. CONCLUSIONS: These voting results by a panel of international experts in advanced prostate cancer can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers prioritise areas for future research. Diagnostic and treatment decisions should always be individualised based on patient and cancer characteristics (disease extent and location, treatment history, comorbidities, and patient preferences) and should incorporate current and emerging clinical evidence, therapeutic guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2022 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials. PATIENT SUMMARY: The Advanced Prostate Cancer Consensus Conference (APCCC) provides a forum to discuss and debate current diagnostic and treatment options for patients with advanced prostate cancer. The conference aims to share the knowledge of international experts in prostate cancer with health care providers and patients worldwide. At each APCCC, a panel of physician experts vote in response to multiple-choice questions about their clinical opinions and approaches to managing advanced prostate cancer. This report presents voting results for the subset of questions pertaining to intermediate- and high-risk and locally advanced prostate cancer, biochemical relapse after definitive treatment, advanced (next-generation) imaging, and management of side effects caused by hormonal therapies. The results provide a practical guide to help clinicians and patients discuss treatment options as part of shared multidisciplinary decision-making. The findings may be especially useful when there is little or no high-level evidence to guide treatment decisions.
Authors
Gillessen, S; Bossi, A; Davis, ID; de Bono, J; Fizazi, K; James, ND; Mottet, N; Shore, N; Small, E; Smith, M; Sweeney, C; Tombal, B; Antonarakis, ES; Aparicio, AM; Armstrong, AJ; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Blanchard, P; Briganti, A; Bristow, RG; Bulbul, M; Caffo, O; Castellano, D; Castro, E; Cheng, HH; Chi, KN; Chowdhury, S; Clarke, CS; Clarke, N; Daugaard, G; De Santis, M; Duran, I; Eeles, R; Efstathiou, E; Efstathiou, J; Ngozi Ekeke, O; Evans, CP; Fanti, S; Feng, FY; Fonteyne, V; Fossati, N; Frydenberg, M; George, D; Gleave, M; Gravis, G; Halabi, S; Heinrich, D; Herrmann, K; Higano, C; Hofman, MS; Horvath, LG; Hussain, M; Alicja Jereczek-Fossa, B; Jones, R; Kanesvaran, R; Kellokumpu-Lehtinen, P-L; Khauli, RB; Klotz, L; Kramer, G; Leibowitz, R; Logothetis, CJ; Mahal, BA; Maluf, F; Mateo, J; Matheson, D; Mehra, N; Merseburger, A; Morgans, AK; Morris, MJ; Mrabti, H; Mukherji, D; Murphy, DG; Murthy, V; Nguyen, PL; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Pezaro, C; Poon, DMC; Pritchard, CC; Rabah, DM; Rathkopf, D; Reiter, RE; Rubin, MA; Ryan, CJ; Saad, F; Pablo Sade, J; Sartor, OA; Scher, HI; Sharifi, N; Skoneczna, I; Soule, H; Spratt, DE; Srinivas, S; Sternberg, CN; Steuber, T; Suzuki, H; Sydes, MR; Taplin, M-E; Tilki, D; Türkeri, L; Turco, F; Uemura, H; Uemura, H; Ürün, Y; Vale, CL; van Oort, I; Vapiwala, N; Walz, J; Yamoah, K; Ye, D; Yu, EY; Zapatero, A; Zilli, T; Omlin, A
URI
https://scholars.duke.edu/individual/pub1559016
PMID
36494221
Source
pubmed
Published In
Eur Urol
Published Date
DOI
10.1016/j.eururo.2022.11.002

The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)

Authors
Gupta, S; Yang, Q; Halabi, S; Tubbs, A; Gore, Y; George, DJ; Nanus, DM; Antonarakis, ES; Danila, D; Szmulewitz, R; Wenstrup, RJ; Armstrong, AJ
MLA Citation
Gupta, S., et al. “The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC).” Annals of Oncology, vol. 33, no. 7, 2022, pp. S1165–66.
URI
https://scholars.duke.edu/individual/pub1559926
Source
wos-lite
Published In
Annals of Oncology
Volume
33
Published Date
Start Page
S1165
End Page
S1166

Research Areas:

Adenocarcinoma
Adenocarcinoma, Clear Cell
African Americans
Age Factors
Aged, 80 and over
Alkaline Phosphatase
Alleles
Arab countries
Area Under Curve
Biological Markers
Biomarkers, Pharmacological
Breast Neoplasms
Cancer Vaccines
Carcinoma
Carcinoma, Renal Cell
Case-Control Studies
Chemoprevention
Chemotherapy
Chi-Square Distribution
Clinical Trials, Phase II as Topic
Clinical trials
Cohort Studies
Computer Simulation
Confidence Intervals
Construction Materials
Contraceptives, Oral
DNA Damage
DNA Primers
DNA Repair
DNA, Neoplasm
Data Interpretation, Statistical
Decision Making
Decision Support Techniques
Diagnostic Imaging
Disease Progression
Disease-Free Survival
Drug Design
Dust
Efficiency, Organizational
Endpoint Determination
Equipment Design
Factor Analysis, Statistical
Family relationships
Gels
Gene Expression
Genes, Immunoglobulin
Genetic Predisposition to Disease
Genetics, Medical
Genotype
Germany
Graft vs Host Disease
HIV Infections
Hispanic Americans
Individualized Medicine
Kaplan-Meier Estimate
Ketoconazole
Lasso
Logistic Models
Lymphokines
Mining
Models, Biological
Models, Statistical
Models, Theoretical
Molecular Sequence Data
Multiprotein Complexes
Multivariate Analysis
Mutation
Neoplasms, Hormone-Dependent
Nomograms
Odds Ratio
Outcome Assessment (Health Care)
Ovarian Neoplasms
Personalized medicine
Population
Population Surveillance
Precision Medicine
Predictive Value of Tests
Pregnancy
Probability
Prognosis
Proportional Hazards Models
Prospective Studies
ROC Curve
Randomized Controlled Trials as Topic
Receptors, Progesterone
Registries
Reproducibility of Results
Research Design
Residence Characteristics
Retrospective Studies
Ribosomal Protein S6 Kinases
Risk
Risk Assessment
Risk Factors
Sample Size
Selective Estrogen Receptor Modulators
Sensitivity and Specificity
Statistics as Topic
Survival
Survival Analysis
Survival Rate
Tamoxifen
Translocation, Genetic
Treatment Failure
Treatment Outcome
Tumor Markers, Biological
United States
Urologic Neoplasms
Validation Studies as Topic
Vascular Endothelial Growth Factors